A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Trial Profile

A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Efgartigimod (Primary) ; Efgartigimod (Primary)
  • Indications Idiopathic thrombocytopenic purpura; Myasthenia gravis; Pemphigus vulgaris
  • Focus Adverse reactions
  • Sponsors argenx
  • Most Recent Events

    • 14 Jun 2018 According to an Argenx media release, argenx announces results from this trial.
    • 04 May 2018 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
    • 01 Mar 2018 According to an Argenx media release, Company expects to report full data from this trial during the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top